Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palovarotene for FOP Flare-ups
NCT02190747Phase 2Completed
- Sponsor
- Clementia Pharmaceuticals Inc.
- Start
- Jul 2014
- Primary completion
- May 2016
- Modality
- Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of palovarotene in fibrodysplasia ossificans progressiva (FOP) (3 arms), sponsored by Clementia Pharmaceuticals Inc. Primary endpoint: Percentage of Responders at Week 6. Started Jul 2014; status: completed.
02
Drugs
palovarotene
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on NCT02190747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02190747.